Interim Report January - June 2008 Tripep AB (publ)

Interim Report January - June 2008 Tripep AB (publ)

 Research and development costs amounted to SEK 11.8 (7.7) million
 The loss after tax was SEK -18.1 (-13.8) million
 Earnings per share were SEK -2.57 (-2.54)
 The company had no net sales for the period
 A reverse stock split 1:10 has been carried out
 The company intends to carry out a rights issue during third quarter 2008.
Some of the major suppliers have agreed to postpone their invoicing pending the
capital injection from the upcoming rights issue
 The ChronVac-C®study shows positive efficacy data i.e activation of immune
responses and lowering of viral levels in the blood in hepatitis C patients
 The first nine patients in the ChronVac-C®study either have concluded or are
in treatment without any serious side effects
 Patent application filed for a new antibiotic-free formulation of ChronSeal®
in collaboration with Kringle Pharma, Inc.
 New application filed with the Swedish Medical Products Agency for a phase II
trial on ChronSeal®
 Tripep secured a first US patent on a new type of immunotherapy against HIV-1

For more information, please contact:
Jan Nilsson, CEO, Tripep AB			
Tel: +46 8 449 84 80, cell: +46 70 466 31 63, 		
e-mail: jan.nilsson@tripep.se		

Anders Vahlne, Head of Research, Tripep AB
Tel: +46 8 5858 1313, cell: +46 70928 05 28,
e-mail: anders.vahlne@ki.se	 


Tripep develops drugs against chronic disease based on proprietary and other
parties' patented and patent pending technologies. Tripep is focusing on the
following research projects; wound healing therapy ChronSeal® and a therapeutic
vaccine against Hepatitis C, named ChronVac-C®, plus the RAS® technology
platform. The Tripep share is admitted to trade on First North. Remium AB is
Certified Adviser for Tripep AB.  For more information, please refer to the
company's Website: www.tripep.se .